NCCN-IPI for DLBCL
NCCN-IPI for DLBCL - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the NCCN-IPI for DLBCL → Runs in your browser. No signup, no tracking.
What this is
NCCN-IPI for DLBCL is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. NCCN-IPI for DLBCL - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842. Read the source ↗
Worked example: NCCN-IPI 4 of 8 -- High-intermediate risk; 5-year overall survival ~64%. Counted: age > 60-75 (2), LDH ratio > 1-3x (1), stage III-IV (1).
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.